Alembic Pharmaceuticals Limited (APLLTD) Price & Analysis

Compare

2 Followers

APLLTD Stock Chart & Stats

₹930.30

-₹4.90(-0.46%)

At close: Jan 09 4:00 PM EST

₹930.30

-₹4.90(-0.46%)

Day’s Range― - ―

52-Week Range₹668.00 - ₹1,107.80

Previous CloseN/A

Volume60.71K

Average Volume (3M)9.71K

Market Cap

₹132.40B

Enterprise Value₹146.20B

Total Cash (Recent Filing)₹1.55B

Total Debt (Recent Filing)₹14.89B

Price to Earnings (P/E)31.3

Beta0.97

Next Earnings

May 06, 2026

EPS Estimate

8.27

Next Dividend Ex-DateN/A

Dividend Yield1.28%

Share Statistics

EPS (TTM)8.90

Shares Outstanding196,563,130

10 Day Avg. Volume3,953

30 Day Avg. Volume9,706

Financial Highlights & Ratios

PEG Ratio-5.74

Price to Book (P/B)3.40

Price to Sales (P/S)2.64

P/FCF Ratio-37.06

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)35.15

Revenue Forecast (FY)₹74.07B

Bulls Say, Bears Say

Bulls Say

Consistent Revenue GrowthAlembic has delivered sustained top-line expansion (≈13.2% revenue growth), reflecting market share gains and product adoption across domestic branded and international generics. Durable revenue growth supports scale economics and provides a platform for reinvestment over 2–6 months.

Improving Gross And EBIT MarginsReported improvements in gross profit and EBIT margins indicate the company is capturing operational leverage from its portfolio and cost structure. Sustained margin expansion improves cash generation potential and resilience to pricing pressure over the medium term.

Diversified, Vertically Integrated Business ModelAlembic’s mix of branded domestic sales, regulated-market generics and an in‑house API business creates multiple revenue streams and supply integration. Vertical integration lowers input risk, supports margins and reduces reliance on any single market segment over time.

Bears Say

Weaker Cash Conversion / Declining FCFFree cash flow has declined as capex rose and operating cash conversion weakened, reducing internally available funds. This can constrain capital allocation, slow deleveraging or limit returns to shareholders, requiring external financing if trends persist beyond a few quarters.

Rising LeverageAn increase in debt-to-equity raises financial risk and interest burden, reducing flexibility to invest or withstand market shocks. Higher leverage can amplify earnings volatility and limit strategic options, making balance sheet management a key medium-term risk.

Net Margin Volatility / Cost ManagementFluctuating net margins point to inconsistent control of operating costs or pricing pressures across segments. Margin variability undermines earnings predictability and weakens the reliability of cash flows for investment and debt servicing over subsequent quarters.

Alembic Pharmaceuticals Limited News

Alembic Pharmaceuticals Forms Thailand Subsidiary to Expand Southeast Asia Footprint

An announcement from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) is now available. Alembic Pharmaceuticals Limited has incorporated a...

8d ago

Alembic Pharma Wins USFDA Nod for $500 Million Efinaconazole Generic

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an announcement. Alembic Pharmaceuticals Limited has received final approval from...

21d ago

Alembic Pharmaceuticals Board Clears Q3 FY26 Unaudited Results, Appoints New Non-Executive Director

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has provided an update. Alembic Pharmaceuticals Limited’s Board of Directors has approved...

1M ago

Alembic Pharmaceuticals Sets Q3 FY26 Post-Results Call for Investors

An update from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) is now available. Alembic Pharmaceuticals has scheduled a post-results...

2M ago

Alembic Pharmaceuticals Schedules Investor Meeting with ICICI Prudential

The latest update is out from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ). Alembic Pharmaceuticals Limited has announced a...

3M ago

Alembic Pharmaceuticals Gains USFDA Approval for Diltiazem Tablets

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an update. Alembic Pharmaceuticals Limited has received final approval from...

4M ago

Alembic Pharmaceuticals Initiates Transfer of Unclaimed Shares

The latest update is out from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ). Alembic Pharmaceuticals Limited has announced a...

4M ago

Alembic Pharmaceuticals Schedules Post-Results Conference Call

An update from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) is now available. Alembic Pharmaceuticals Limited has announced a...

5M ago

Alembic Pharmaceuticals Updates Registrar’s Email for Improved Communication

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has shared an update. Alembic Pharmaceuticals Limited has announced a change in...

6M ago

Alembic Pharmaceuticals Gains USFDA Approval for Tretinoin Cream

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an announcement. Alembic Pharmaceuticals Limited has announced that it received...

7M ago

APLLTD FAQ

What was Alembic Pharmaceuticals Limited’s price range in the past 12 months?

Alembic Pharmaceuticals Limited lowest stock price was ₹668.00 and its highest was ₹1107.80 in the past 12 months.

What is Alembic Pharmaceuticals Limited’s market cap?

Alembic Pharmaceuticals Limited’s market cap is ₹132.40B.

When is Alembic Pharmaceuticals Limited’s upcoming earnings report date?

Alembic Pharmaceuticals Limited’s upcoming earnings report date is May 06, 2026 which is in 50 days.

How were Alembic Pharmaceuticals Limited’s earnings last quarter?

Alembic Pharmaceuticals Limited released its earnings results on Feb 05, 2026. The company reported ₹8.9 earnings per share for the quarter, beating the consensus estimate of ₹8.372 by ₹0.528.

Is Alembic Pharmaceuticals Limited overvalued?

According to Wall Street analysts Alembic Pharmaceuticals Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alembic Pharmaceuticals Limited pay dividends?

Alembic Pharmaceuticals Limited pays a Annually dividend of ₹11 which represents an annual dividend yield of 1.28%. See more information on Alembic Pharmaceuticals Limited dividends here

What is Alembic Pharmaceuticals Limited’s EPS estimate?

Alembic Pharmaceuticals Limited’s EPS estimate is 8.27.

How many shares outstanding does Alembic Pharmaceuticals Limited have?

Alembic Pharmaceuticals Limited has 196,563,130 shares outstanding.

What happened to Alembic Pharmaceuticals Limited’s price movement after its last earnings report?

Alembic Pharmaceuticals Limited reported an EPS of ₹8.9 in its last earnings report, beating expectations of ₹8.372. Following the earnings report the stock price went up 1.409%.

Which hedge fund is a major shareholder of Alembic Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:APLLTD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, and anti-diabetic. In addition, it exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.